$MD
Pediatrix Medical Group, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024119796 Filed on November 01, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $511.2M
YoY Change 0.9%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $423.0M
YoY Change -0.66%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $6.254M
YoY Change -32.1%
% of Gross Profit
Operating Expenses $477.3M
YoY Change 2.36%
Operating Profit $33.83M
YoY Change -16.0%
Interest Expense -$8.592M
YoY Change -182.82%
% of Operating Profit -25.4%
Other Income/Expense, Net -$8.592M
YoY Change -8.98%
Pretax Income $25.24M
YoY Change -18.15%
Income Tax $5.794M
% Of Pretax Income 22.96%
Net Earnings $19.44M
YoY Change -9.12%
Net Earnings / Revenue 3.8%
Basic Earnings Per Share $0.23
Diluted Earnings Per Share $0.23
COMMON SHARES
Basic Shares Outstanding 85.88M 85.87M
Diluted Shares Outstanding 84.52M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $220.5M
YoY Change 76.76%
Cash & Equivalents $103.8M
Short-Term Investments $116.6M
Other Short-Term Assets $9.480M
YoY Change 20.52%
Inventory
Prepaid Expenses $10.19M
Receivables $286.9M
Other Receivables $1.198M
Total Short-Term Assets $528.2M
YoY Change 25.61%
LONG-TERM ASSETS
Property, Plant & Equipment $41.92M
YoY Change -44.21%
Goodwill $1.239B
YoY Change -19.13%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $78.59M
YoY Change -27.23%
Total Long-Term Assets $1.549B
YoY Change -18.74%
TOTAL ASSETS
Total Short-Term Assets $528.2M
Total Long-Term Assets $1.549B
Total Assets $2.077B
YoY Change -10.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $47.37M
YoY Change 49.44%
Accrued Expenses $303.1M
YoY Change 3.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $19.28M
YoY Change 29.12%
Total Short-Term Liabilities $373.1M
YoY Change 6.46%
LONG-TERM LIABILITIES
Long-Term Debt $607.4M
YoY Change -2.29%
Other Long-Term Liabilities $33.04M
YoY Change 5.92%
Total Long-Term Liabilities $33.04M
YoY Change 5.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $373.1M
Total Long-Term Liabilities $33.04M
Total Liabilities $1.344B
YoY Change -1.03%
SHAREHOLDERS EQUITY
Retained Earnings -$279.0M
YoY Change 1007.93%
Common Stock $1.012B
YoY Change 1.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $732.5M
YoY Change
Total Liabilities & Shareholders Equity $2.077B
YoY Change -10.72%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income $19.44M
YoY Change -9.12%
Depreciation, Depletion And Amortization $6.254M
YoY Change -32.1%
Cash From Operating Activities $91.84M
YoY Change 14.89%
INVESTING ACTIVITIES
Capital Expenditures $6.290M
YoY Change -31.29%
Acquisitions
YoY Change
Other Investing Activities $1.952M
YoY Change -140.25%
Cash From Investing Activities -$4.338M
YoY Change -69.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -3.071M
YoY Change -93.93%
NET CHANGE
Cash From Operating Activities 91.84M
Cash From Investing Activities -4.338M
Cash From Financing Activities -3.071M
Net Change In Cash 84.43M
YoY Change 450.74%
FREE CASH FLOW
Cash From Operating Activities $91.84M
Capital Expenditures $6.290M
Free Cash Flow $85.55M
YoY Change 20.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0000893949
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-12111
dei Entity Registrant Name
EntityRegistrantName
Pediatrix Medical Group, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
FL
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-3667538
dei Entity Address Address Line1
EntityAddressAddressLine1
1301 Concord Terrace
dei Entity Address City Or Town
EntityAddressCityOrTown
Sunrise
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33323
dei City Area Code
CityAreaCode
954
dei Local Phone Number
LocalPhoneNumber
384-0175
dei Security12b Title
Security12bTitle
Common Stock, par value $.01 per share
dei Trading Symbol
TradingSymbol
MD
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
85880487
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103831000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
73258000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
116621000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
104485000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
286897000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
272313000
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10188000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
13525000
CY2024Q3 us-gaap Income Tax Receivable
IncomeTaxReceivable
1198000
CY2023Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
7565000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
9480000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
12308000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
528215000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
483454000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
41922000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
75639000
CY2024Q3 us-gaap Goodwill
Goodwill
1239007000
CY2023Q4 us-gaap Goodwill
Goodwill
1384166000
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
13183000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
21240000
CY2024Q3 md Operating And Finance Lease Right Of Use Assets
OperatingAndFinanceLeaseRightOfUseAssets
56566000
CY2023Q4 md Operating And Finance Lease Right Of Use Assets
OperatingAndFinanceLeaseRightOfUseAssets
70294000
CY2024Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
119386000
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
102852000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
78594000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
82165000
CY2024Q3 us-gaap Assets
Assets
2076873000
CY2023Q4 us-gaap Assets
Assets
2219810000
CY2024Q3 md Accounts Payable And Accrued Liabilities Excluding Accrued Income Taxes Current
AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
333493000
CY2023Q4 md Accounts Payable And Accrued Liabilities Excluding Accrued Income Taxes Current
AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
350798000
CY2024Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
19276000
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
14913000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
16992000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
21076000
CY2024Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
3319000
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2159000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
373080000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
388946000
CY2024Q3 md Long Term Debt And Capital Lease Obligations Excluding Long Term Line Of Credit
LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
607445000
CY2023Q4 md Long Term Debt And Capital Lease Obligations Excluding Long Term Line Of Credit
LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
618421000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
39940000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
47238000
CY2024Q3 us-gaap Malpractice Loss Contingency Accrual Undiscounted Noncurrent
MalpracticeLossContingencyAccrualUndiscountedNoncurrent
255263000
CY2023Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted Noncurrent
MalpracticeLossContingencyAccrualUndiscountedNoncurrent
251284000
CY2024Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
35618000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
34308000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
33035000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
30552000
CY2024Q3 us-gaap Liabilities
Liabilities
1344381000
CY2023Q4 us-gaap Liabilities
Liabilities
1370749000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
85865841
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
85865841
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
84018023
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
84018023
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
859000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
840000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1010862000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
999906000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-209000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2214000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-279020000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-149471000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
732492000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
849061000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2076873000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2219810000
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
511158000
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
506612000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1510555000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1498197000
CY2024Q3 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
364888000
CY2023Q3 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
368404000
md Practice Salaries And Benefits
PracticeSalariesAndBenefits
1091834000
md Practice Salaries And Benefits
PracticeSalariesAndBenefits
1084671000
CY2024Q3 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
29449000
CY2023Q3 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
31319000
md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
92903000
md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
93128000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
58121000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
57406000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
174884000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
174478000
CY2024Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6254000
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9211000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
25353000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
27109000
CY2024Q3 us-gaap Restructuring Charges
RestructuringCharges
18560000
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
0
us-gaap Restructuring Charges
RestructuringCharges
40619000
us-gaap Restructuring Charges
RestructuringCharges
0
CY2024Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
154243000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2024Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
20112000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2024Q3 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2023Q3 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
7679000
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2024Q3 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-59000
CY2023Q3 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-10932000
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
477331000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
466340000
us-gaap Operating Expenses
OperatingExpenses
1618559000
us-gaap Operating Expenses
OperatingExpenses
1379386000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
33827000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
40272000
us-gaap Operating Income Loss
OperatingIncomeLoss
-108004000
us-gaap Operating Income Loss
OperatingIncomeLoss
118811000
CY2024Q3 us-gaap Investment Income Net
InvestmentIncomeNet
1089000
CY2023Q3 us-gaap Investment Income Net
InvestmentIncomeNet
273000
us-gaap Investment Income Net
InvestmentIncomeNet
2941000
us-gaap Investment Income Net
InvestmentIncomeNet
2096000
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
10126000
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
10374000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
31033000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
31994000
CY2024Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
445000
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
661000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1427000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1578000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8592000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9440000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-26665000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-28320000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
25235000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
30832000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-134669000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
90491000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5794000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9441000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5120000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
26612000
CY2024Q3 us-gaap Profit Loss
ProfitLoss
19441000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
21391000
us-gaap Profit Loss
ProfitLoss
-129549000
us-gaap Profit Loss
ProfitLoss
63879000
CY2024Q3 md Net Of Tax Unrealized Holding Gain Loss On Investments
NetOfTaxUnrealizedHoldingGainLossOnInvestments
571000
md Net Of Tax Unrealized Holding Gain Loss On Investments
NetOfTaxUnrealizedHoldingGainLossOnInvestments
657000
md Net Of Tax Unrealized Holding Gain Loss On Investments
NetOfTaxUnrealizedHoldingGainLossOnInvestments
100000
CY2024Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
1745000
CY2023Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
1000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
2005000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
218000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
21186000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
21392000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-127544000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
64097000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.78
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.23
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.77
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83891000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82543000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83223000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82127000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
84523000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82950000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83223000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82492000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
849061000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
4035000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
60000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
860000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3067000
CY2024Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
887000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
856196000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-153025000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
200000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1149000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1952000
CY2024Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
11000
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
706461000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
19441000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1745000
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
897000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4110000
CY2024Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
162000
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
732492000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
891632000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
14206000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
604000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1095000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3009000
CY2023Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
775000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
909771000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
28282000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-387000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1594000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3126000
CY2023Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
11000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
942375000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
21391000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1187000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3164000
CY2023Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
133000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
967985000
us-gaap Net Income Loss
NetIncomeLoss
-129549000
us-gaap Net Income Loss
NetIncomeLoss
63879000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
25353000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
27109000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
703000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1015000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
154243000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
20112000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
7679000
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-10932000
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0
us-gaap Share Based Compensation
ShareBasedCompensation
9129000
us-gaap Share Based Compensation
ShareBasedCompensation
9299000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-15880000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
10589000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2006000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1607000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-635000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-22095000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5945000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4290000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-30569000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-13343000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-34154000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-56118000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
7527000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-5154000
us-gaap Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve
IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
13239000
us-gaap Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve
IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
838000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-22032000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-16500000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
82445000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
73078000
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-8882000
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-5003000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
73563000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
68075000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
8167000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
1667000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
54402000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
26477000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
45324000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
16560000
us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
18582000
us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
24284000
us-gaap Proceeds From Sale Of Other Productive Assets
ProceedsFromSaleOfOtherProductiveAssets
2359000
us-gaap Proceeds From Sale Of Other Productive Assets
ProceedsFromSaleOfOtherProductiveAssets
116000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-33468000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35752000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
235500000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
470000000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
235500000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
474000000
md Payments To Term Loan
PaymentsToTermLoan
9375000
md Payments To Term Loan
PaymentsToTermLoan
9375000
md Repayments Of Long Term Capital Lease Obligation
RepaymentsOfLongTermCapitalLeaseObligation
2045000
md Repayments Of Long Term Capital Lease Obligation
RepaymentsOfLongTermCapitalLeaseObligation
2105000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2906000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3876000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1060000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
919000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
52000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-8445000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-9522000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-20968000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
30573000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11355000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
73258000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9824000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
103831000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21179000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
116621000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
104485000
CY2024Q3 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1469676000
CY2023Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1379213000
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1182779000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1106900000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
286897000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
272313000
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
511158000
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
506612000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1510555000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1498197000
CY2024Q3 md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1
CY2023Q3 md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1
md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1
md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1
CY2024Q3 us-gaap Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount
BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
9100000
CY2024Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
400000
CY2024Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
200000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
20100000
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
7700000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
10600000
CY2024Q2 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-10600000
md Good Will Impairment Loss Excluding Deferred Tax Assets Charge
GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge
130000000
CY2024Q3 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
24200000
md Incremental Non Cash Charge
IncrementalNonCashCharge
24200000
md Non Cash Charge
NonCashCharge
154200000
md Change In Rate Of Control Premium
ChangeInRateOfControlPremium
0.01
md Change In Non Cash Impairment Charges
ChangeInNonCashImpairmentCharges
7700000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
47367000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
34588000
CY2024Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
162554000
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
193112000
CY2024Q3 md Accrued Payroll Taxes And Benefits Current
AccruedPayrollTaxesAndBenefitsCurrent
34327000
CY2023Q4 md Accrued Payroll Taxes And Benefits Current
AccruedPayrollTaxesAndBenefitsCurrent
36545000
CY2024Q3 us-gaap Malpractice Loss Contingency Accrual Undiscounted Current
MalpracticeLossContingencyAccrualUndiscountedCurrent
28966000
CY2023Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted Current
MalpracticeLossContingencyAccrualUndiscountedCurrent
32039000
CY2024Q3 us-gaap Interest Payable Current
InterestPayableCurrent
2789000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
8262000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
57490000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
46252000
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
333493000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
350798000
md Increase Decrease In Accrued Salaries And Bonuses
IncreaseDecreaseInAccruedSalariesAndBonuses
30600000
CY2024Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.05375
us-gaap Debt Instrument Frequency Of Periodic Payment
DebtInstrumentFrequencyOfPeriodicPayment
payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022
us-gaap Debt Instrument Description
DebtInstrumentDescription
Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company's ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits the Company's ability to merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions
CY2024Q3 md Purchase Price
PurchasePrice
1.01
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83891000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82543000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83223000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82127000
CY2024Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
632000
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
407000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
365000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
84523000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82950000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83223000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82492000
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
888000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
389000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1201000
md Incremental Shares Not Included Due To Anti Dilutive Effect
IncrementalSharesNotIncludedDueToAntiDilutiveEffect
400000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2600000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7500000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3200000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9300000
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0
CY2018Q3 srt Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
500000000
CY2023Q4 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
4600000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-24-119796-index-headers.html Edgar Link pending
0000950170-24-119796-index.html Edgar Link pending
0000950170-24-119796.txt Edgar Link pending
0000950170-24-119796-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img260272796_0.jpg Edgar Link pending
md-20240930.htm Edgar Link pending
md-20240930.xsd Edgar Link pending
md-ex10_1.htm Edgar Link pending
md-ex31_1.htm Edgar Link pending
md-ex31_2.htm Edgar Link pending
md-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
md-20240930_htm.xml Edgar Link completed
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending